Lantern Pharma Advances LP-300 Trial After FDA Type C Meeting Supports HARMONIC Phase 2 Design in Never-Smoker Lung Cancer
Lantern Pharma announced a successful outcome from its FDA Type C meeting request, which supports protocol amendments for the ongoing HARMONIC Phase 2 trial of LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC). The FDA provided no objections to key changes, including focusing enrollment on EGFR-mutant patients and shifting toward a single-arm study design to better reflect evolving treatment standards. The updated trial structure is intended to improve patient selection, streamline development, and strengthen the clinical signal of LP-300 in a highly specific lung cancer subgroup. 
Lantern Pharma Advances LP-300 Trial After FDA Type C Meeting Supports HARMONIC Phase 2 Design in Never-Smoker Lung Cancer